ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1625211
This article is part of the Research TopicNew Progress on the Role of Gut Microbiota in the Incidence and Prevention of Liver DiseasesView all 20 articles
Elucidating the Gut Microbiota-Driven Crosstalk: Mechanistic Interplay of Lobetyolin in Coordinating Cholesterol Homeostasis and Anti-Inflammatory Pathways in Hyperlipidemic Mice Models
Provisionally accepted- 1Shanxi Agricultural University, Jinzhong, China
- 2School of Pharmacy, Changzhi Medical CollegeChangzhi, Changzhi city, China
- 3School of nursing, Changzhi Medical College, School of Pharmacy, Changzhi Medical CollegeChangzhi, Changzhi city, China
- 4Changzhi Medical College, Changzhi city, China
- 5School of Nursing, Changzhi Medical College. Changzhi, Shanxi 046000, China_819@, Changzhi city, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hyperlipidemia is a prevalent metabolic disorder closely associated with gut microbiota imbalance. In recent years, traditional Chinese medicine has demonstrated distinct advantages in the regulation of the gut microbiota and enhancement of metabolic health. This study aimed to elucidate the molecular processes by which lobetyolin modifies the gut microbiota to improve intestinal inflammation and lipid metabolism in hyperlipidemic mice.Forty female KM mice were randomly allocated to four groups: control, model, LBT1, and LBT2. Mice in the LBT1 and LBT2 groups received intraperitoneal injections of the corresponding concentrations of LBT for ten consecutive days, whereas mice in the control and model groups received intraperitoneal injections of physiological saline. Beginning on the eighth day, mice in the model, LBT1, and LBT2 groups received subcutaneous injections of Triton WR-1339 for three consecutive days, whereas those in the control group received subcutaneous injections of physiological saline concurrently. On the eleventh day of the experiment, serum, liver, colon, and fecal samples were collected from all mice. This study aimed to measure lipid metabolism in mouse serum and liver, assess the inflammatory status of the mouse colon, and evaluate changes in the gut microbiota.Lobetyolin significantly reduced the levels of triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and total cholesterol (T-CHO) in the serum of hyperlipidemic mice. Concurrently, it elevated the levels of high-density lipoprotein cholesterol (HDL-C). The mechanism involves the reduction of endogenous cholesterol production and promotion of reverse cholesterol transport. LBT can also alleviate inflammatory responses by inhibiting the TLR4/NF -κ B signaling pathway. In addition, it can regulate the balance of Th1 and Th2 immunity and enhance the immune capacity of the colon mucosa. According to the results of 16S rRNA sequencing, LBT increased the abundance of beneficial gut microbiota, such as Akkermansia, Dubosiella, and Lactobacillus, which were positively correlated with HDL-C, IL-10, IL-4, and SIgA but negatively correlated with T-CHO, TG, LDL-C, VLDL-C, IL-6, IFN-γ, and TNF-α.Our findings emphasize that lobetyolin exerts lipid-lowering and anti-inflammatory effects by regulating the ecological structure of the gut microbiota.
Keywords: Enteritis, Hyperlipidemia, Gut Microbiota, Lobetyolin (LBT), Triteron WR-1339
Received: 08 May 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Duan, Zhang, Liu, Wang, Liu, Li and Lai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lijuan Li, School of Nursing, Changzhi Medical College. Changzhi, Shanxi 046000, China_819@, Changzhi city, China
Lina Lai, School of Pharmacy, Changzhi Medical CollegeChangzhi, Changzhi city, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.